Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects

This study has been completed.
Sponsor:
Information provided by:
Merz Pharmaceuticals GmbH
ClinicalTrials.gov Identifier:
NCT00915174
First received: June 4, 2009
Last updated: May 5, 2011
Last verified: May 2011
  Purpose

Primary:

To assess the effects of repeated dose of Neramexane on the steady-state pharmacokinetics of Drospirenone [DRSP] and Ethinyl Estradiol [EE]

Secondary:

To assess safety and tolerability of concomitant repeated dose treatments of Neramexane and a fixed-combinational DRSP- and EE-containing oral contraceptive [OC] (Yasmin®)


Condition Intervention Phase
Healthy
Drug: Neramexane
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)

Resource links provided by NLM:


Further study details as provided by Merz Pharmaceuticals GmbH:

Primary Outcome Measures:
  • Area Under Curve within a dose interval (AUC, 0-tau) and Maximum Plasma Concentration at Steady State (Cmax) of Drospirenone (DRSP) and Ethinyl Estradiol (EE) [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: June 2009
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Neramexane
    25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult female subject of child bearing potential (including subject with tubal ligation), white origin, who is able to read, to write and fully understand German language
  • Aged 18 to 45 years (both inclusive)
  • BMI of 18-28 kg/m2 and a body weight of 50-90 kg (both inclusive)
  • The subject is required
  • To have taken a DRSP/EE- containing OC for at least two dosing cycles
  • To agree using reliable non hormonal birth control methods from Day -1 of study Period 1 until the Final Examination (e.g. non-hormonal IUD, double barrier method [e.g. condom with spermicide or diaphragm with spermicide], sexual abstinence). Women with tubal ligation or sterilized partner do not need an additional birth control method
  • Willing and able to provide written informed consent after having been informed of the requirements and the restrictions of the study

Exclusion Criteria:

  • History of clinically relevant allergy or known hypersensitivity to Neramexane/Memantine/ Amantadine and their derivatives
  • Hypersensitivity to Quinine
  • History of clinically relevant allergy or known hypersensitivity to any inactive ingredient in any of the used study medications (Neramexane, Yasmin®, Placebo) or tool substance
  • History of clinically relevant allergy or known hypersensitivity to DRSP/EE
  • Clinically relevant findings on the mammae or genital examination, PAP smear ≥ III
  • Any contraindications against the oral contraceptive:
  • present or past venous thromboses (deep vein thrombosis, pulmonary embolism);
  • present or past arterial thromboses (e.g. myocardial infarction) or their prodromal stages (e.g. angina pectoris and transitory ischaemic attack);
  • present or past cerebrovascular insult;
  • presence of a serious risk factor or several risk factors for an arterial thrombosis: diabetes mellitus with vascular changes, severe hypertension, severe lipid metabolism disturbance;
  • known or suspected genetic or acquired predisposition for venous or arterial thromboses like APC resistance,
  • known or suspected genetic lack of antithrombin III, lack of protein C, lack of protein S, hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulants);
  • present or past pancreatitis if this is accompanied by severe hypertriglyceridaemia;
  • present or past severe hepatic disease as long as the liver function tests have not normalized;
  • severe renal insufficiency or acute renal failure;
  • present or past hepatic tumors (benign or malign);
  • known or suspected sexual hormone dependent, malign tumors (e.g. of the genital organs or the mamma);
  • diagnostic not clarified vaginal bleedings;
  • anamnesis of migraine with focal neurologic symptoms;
  • known hereditary angioedema
  • Exposure to another investigational agent within the last two months before Day 1 of Period 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00915174

Locations
Germany
AAIharma Deutschland GmbH & Co. KG
Neu Ulm, Bavaria, Germany, 89231
Sponsors and Collaborators
Merz Pharmaceuticals GmbH
Investigators
Study Director: Medical Expert MERZ Pharmaceuticals
  More Information

No publications provided

Responsible Party: Manager Public Disclosure, Merz Pharmaceuticals GmbH
ClinicalTrials.gov Identifier: NCT00915174     History of Changes
Other Study ID Numbers: MRZ 92579/TI/1005
Study First Received: June 4, 2009
Last Updated: May 5, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Merz Pharmaceuticals GmbH:
drug-drug interaction study

Additional relevant MeSH terms:
Contraceptives, Oral
Drospirenone and ethinyl estradiol combination
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on July 26, 2014